EMPA (drug)
EMPA is a selective antagonist of the OX2 receptor, with 900-fold selectivity in binding for OX2 over OX1.[1][2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ECHA InfoCard | 100.233.393 |
Chemical and physical data | |
Formula | C23H26N4O4S |
Molar mass | 454.542 g/mol gยทmolโ1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
See also
References
- Malherbe, P; Borroni, E; Pinard, E; Wettstein, JG; Knoflach, F (2009). "Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists". Mol Pharmacol. 76 (3): 618โ31. doi:10.1124/mol.109.055152. PMID 19542319.
- Malherbe; et al. (2009). "Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor". Br. J. Pharmacol. 156 (8): 1326โ41. doi:10.1111/j.1476-5381.2009.00127.x. PMC 2697736. PMID 19751316.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.